FMR LLC grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 30.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 81,983,231 shares of the company's stock after purchasing an additional 19,242,468 shares during the period. FMR LLC owned about 7.24% of Teva Pharmaceutical Industries worth $1,806,910,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Diversify Advisory Services LLC lifted its holdings in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after buying an additional 496 shares in the last quarter. Sanctuary Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after acquiring an additional 664 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares during the period. Metis Global Partners LLC grew its stake in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after purchasing an additional 860 shares in the last quarter. Finally, DGS Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after purchasing an additional 872 shares during the period. 54.05% of the stock is currently owned by institutional investors.
Teva Pharmaceutical Industries Stock Up 4.7 %
NYSE:TEVA traded up $0.60 during midday trading on Friday, reaching $13.42. 12,222,912 shares of the stock traded hands, compared to its average volume of 9,939,000. The stock has a market capitalization of $15.22 billion, a PE ratio of -9.26, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business has a 50-day moving average of $15.79 and a two-hundred day moving average of $17.82.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the company. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.
View Our Latest Research Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
